Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of Velsecorat (AZD7594) in Adolescents with Asthma
NCT03976869Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2019
- Primary completion
- Jul 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of velsecorat in asthma, sponsored by AstraZeneca. Primary endpoints: Maximum observed plasma concentration at steady state at Day 15, Minimum observed plasma concentration at steady state at Day 15 and 5 more. Started Jul 2019; status: completed.
02
Drugs
velsecorat
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03976869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03976869.